In last trading session, Enliven Therapeutics Inc (NASDAQ:ELVN) saw 0.48 million shares changing hands with its beta currently measuring 1.02. Company’s recent per share price level of $22.65 trading at $1.66 or 7.91% at ring of the bell on the day assigns it a market valuation of $1.06B. That closing price of ELVN’s stock is at a discount of -14.79% from its 52-week high price of $26.00 and is indicating a premium of 56.73% from its 52-week low price of $9.80. Taking a look at company’s average trading volume volume of 275.93K if we extend that period to 3-months.
Enliven Therapeutics Inc (NASDAQ:ELVN) trade information
Upright in the green during last session for gaining 7.91%, in the last five days ELVN remained trading in the green while hitting it’s week-highest on Friday, 05/03/24 when the stock touched $22.65 price level, adding 1.52% to its value on the day. Enliven Therapeutics Inc’s shares saw a change of 63.66% in year-to-date performance and have moved 31.84% in past 5-day. Enliven Therapeutics Inc (NASDAQ:ELVN) showed a performance of 21.77% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Enliven Therapeutics Inc (ELVN) estimates and forecasts
Statistics highlight that Enliven Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 90.82% of value to its shares in past 6 months, showing an annual growth rate of -7.46% while that of industry is 11.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.16% during past 5 years.
ELVN Dividends
Enliven Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
